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Abstract
Background: There are several limitations in diagnosing plasma leakage using the World Health Organization
(WHO) guidelines of dengue hemorrhagic fever. We conducted a study to develop a dengue scoring system to
predict pleural effusion and/or ascites using routine laboratory parameters.
Methods: A prospective observational study was carried out at Cipto Mangunkusumo Hospital and Persahabatan
Hospital, Jakarta, Indonesia. Dengue-infected adults admitted on the third febrile day from March, 2010 through
August, 2015 were included in the study. A multivariate analysis was conducted to determine the independent
diagnostic predictors of pleural effusion and/or ascites and to convert the prediction model into a scoring system.
Results: A total of 172 dengue-infected adults were enrolled in the study. Of the 172 patients, 101 (58.7 %)
developed pleural effusion and/or ascites. A multivariate analysis was conducted to determine the independent
diagnostic predictors of pleural effusion and/or ascites in dengue-infected adults. The predictors were scored based
on the following calculations: hemoconcentration ≥15.1 % had a score of 1 (OR, 3.11; 95 % CI, 1.41–6.88), lowest
albumin concentration at critical phase ≤3.49 mg/dL had a score of 1 (OR, 4.48; 95 % CI, 1.87–10.77), lowest platelet
count ≤49,500/μL had a score of 1 (OR, 3.62; 95 % CI, 1.55–8.49), and elevated ratio of AST ≥2.51 had a score of 1
(OR 2.67; 95 % CI, 1.19–5.97). At a cut off of≥ 2, the Dengue Score predicted pleural effusion and/or ascites
diagnosis with positive predictive value of 79.21 % and negative predictive value of 74.63 %. This prediction model
is suitable for calibration and good discrimination.
Conclusions: We have developed a Dengue Score that could be used to identify pleural effusion and/or ascites
and might be useful to stratify dengue-infected patients at risk for developing severe dengue.
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Background
Two-fifths of the world’s populations in tropical and sub-
tropical countries are at risk of dengue. An estimated
500,000 people with dengue infection require
hospitalization each year [1, 2]. Based on a 20-year registry
of dengue infection age based-epidemiology in Indonesia,
there appears to be an epidemiological shift in the age of
affected individuals. Since 1999, a steady decline in inci-
dence was observed for children aged 5 to 14 years (the
age group with highest DHF incidence, historically). The
decline surpassed the increasing incidence of affected in-
dividuals aged over 15 years [3].
The presence of plasma leakage, one of the character-
istics of dengue hemorrhagic fever (DHF), is the promin-
ent cause of severe dengue [4, 5]. The timely diagnosis
and management of plasma leakage are very important
[4]. Fujimoto et al. reported that 5.7 % of patients with
plasma leakage developed cardiorespiratory dysfunction,
and the mortality rate reached 7.3 % [6]. Chairulfatah
et al. reported 6 % severe bleeding in 1300 pediatric and
adult DHF cases in Indonesia [7].
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The World Health Organization (WHO) guidelines de-
fined plasma leakage with the occurrence of hemoconcen-
tration and/or hypoalbuminemia and/or serous effusion
[2, 5, 8–10]. However, there are several limitations in diag-
nosing plasma leakage using these criteria. In clinical prac-
tice, clinicians often detect pleural effusion and/or ascites
in patients with elevated hematocrit values of less than
20 %, a cut off used to define hemoconcentration as rec-
ommended by WHO (1, 8, 9). Moreover, previous studies
showed albumin level <3.5 g/dL in dengue fever (DF) and
DHF patients, which is in contrast with WHO criteria that
use 3.5 g/dL to differentiate patients with and without
plasma leakage [2, 11–14]. Compared with hematocrit
and albumin level, pleural effusions and/or ascites as visu-
alized by ultrasonography (USG) are highly sensitive and
specific for determining plasma leakage [15–18]. However,
USG is not widely available in resource limited areas [19].
Despite the currently accepted laboratory parameters for
determining plasma leakage, pathophysiologically there
are associations between plasma leakage identified by the
presence of pleural effusions and/or ascites with
thrombocytopenia and elevated hepatic transaminase
levels [20, 21]. To the best of our knowledge, there are no
studies reporting the cut off point of the lowest platelet
count and elevated ratio of transaminase levels at the crit-
ical phase for diagnosing pleural effusion and/or ascites.
Similarly, no reports regarding the cut off point of hypo-
natremia, which is another common manifestation of
plasma leakage [10], is available.
Here, we conducted a study to develop a dengue scoring
system to predict pleural effusion and/or ascites using la-
boratory parameters, such as the degree of hemoconcen-
tration, lowest albumin concentration at the critical phase,
degree of hypoalbuminemia, lowest platelet count, ele-
vated ratio of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and sodium concentration at crit-
ical phase. This Dengue Score can be used to identify
pleural effusions and/or ascites, which are better indica-
tors of plasma leakage, to stratify dengue-infected patients
at risk of developing severe dengue.
Methods
Patients and study design
This was a prospective observational study conducted
at the ward of Cipto Mangunkusumo and Persahabatan
Hospitals, Jakarta, Indonesia. Dengue-infected patients
admitted on the third febrile day from March 2010
through August 2015 were included in the study. Adult
patients aged 14 years or above were included. Dengue
infection was diagnosed when acute febrile patients
with axillary temperature above 37.5 °C were proven
positive for dengue nonstructural protein (NS) 1
antigen test (Standard Diagnostics, Korea). The exclu-
sion criteria included pregnant women, patients with
comorbidities and patients who were not willing to
participate.
Dengue virus (DENV) serotyping and clinical laboratory
examination
DENV serotypes were determined using both conven-
tional RT-PCR according to method by Lanciotti et al.
[22] and Simplexa Dengue real-time RT-PCR (Focus
Diagnostics, Cypress, CA, USA) [23]. Virus RNA was ex-
tracted directly from 140 μl serum samples using
QIAamp viral RNA mini kit (Qiagen, Hilden, Germany),
performed according to the manufacturer’s instructions.
The resulting RNAs were subjected to RT-PCR assays.
The patients’ characteristics, onset of fever, and clinical
findings were recorded for each subject upon arrival at
the emergency department for enrollment. A complete
blood count, including hematocrit level, platelet count,
and albumin level were performed daily until the sub-
jects met the discharge criteria based on the WHO
guidelines [5]. Hepatic transaminases (AST and ALT)
levels and sodium concentrations were measured twice
during the critical phase as defined by 24–48 h after de-
fervescence. Abdominal USG to detect pleural effusions
and/or ascites using conventional ultrasound devices
with a 3.5 MHz transducer were performed by a certified
radiologist 24 h after defervescence [5]. To validate the
USG results, another certified radiologist examined the
ultrasonogram of every subject.
The degree of hemoconcentration (%) was calculated
according to the formula of subtracting the peak
hematocrit with the minimum hematocrit recorded, then
dividing that value by the minimum hematocrit recorded
and multiplying by 100 (Fig. 1). The degree of hypoalbu-
minemia (%) was calculated according to the formula of
subtracting the peak albumin with the minimum albumin
level recorded, divided by the peak albumin level and
multiplying by 100 (Fig. 1). Elevated ratios of AST or ALT
were calculated by dividing the peak AST or ALT in the
critical phase by the upper reference limit (Fig. 1).
Statistical analysis
The sample size of the study was based on an estimated
48 % prevalence of hemoconcentration in subjects with
pleural effusion and/or ascites [24]. Assuming an odds
ratio of 1.75, with α = 0.05 and β = 0.20, the required
total sample size was calculated to be 168 patients.
A bivariate analysis with student’s t-test for normally
distributed data and a Mann Whitney test for non-
parametric data were performed to identify variables that
had a significant association with the presence of pleural
effusion and/or ascites. To determine the appropriate
cut off values of each significant variable (p < 0.05), the
receiving operating characteristic (ROC) curve analysis
was used to obtain the best sensitivity and specificity for
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a diagnosis of pleural effusion and/or ascites. These best
cut off values were used to classify the subjects into cat-
egorical variables. All of the categorical variables had a
significant effect based on bivariate analysis and were
then submitted to multivariate analysis.
We entered the variables into a multiple regression
analysis using a backward selection algorithm to esti-
mate the coefficients and independent diagnostic predic-
tors of pleural effusion and/or ascites. The coefficients
were converted into a simplified risk score system using
published methods [25–27]. The performance of the
model was assessed by the Hosmer Lemeshow test for
its calibration and by an area under receiving operating
characteristic curve (AROC) for its discriminating abil-
ity. Statistical analyses were performed using the STATA
statistical software version 12 (Stata Corp., College Sta-
tion, TX, USA).
Results
Patients’ characteristics and clinical laboratory parameters
A total of 172 dengue infected-patients were enrolled in
the study; the patients had a median age of 22 (inter-
quartile range = 11) years old, and 89 (51.7 %) were men.
Most patients (34.3 %) were infected with DENV-2 . Of
the 172 patients, 101 (58.7 %) developed a pleural effu-
sion and/or ascites. The characteristics of the subjects
are presented in Table 1.
Six of seven diagnostic predictors of pleural effusion
and/or ascites were found to have a significant associ-
ation with the presence of pleural effusion and/or ascites
Hemoconcentration (%) = × 100
Albuminemia (%) = × 100
AST =  
ALT
=  
Fig. 1 Formulae for calculating the degrees of hemoconcentration, albuminemia, and the ratios of AST and ALT
Table 1 Dengue infected-patients: comparison of patients with and without pleural effusion and/or ascites
Variable Without pleural effusion and/or ascites
(n = 71)
With pleural effusion and/or ascites
(n = 101)
Sex (n, male/female) 32/39 57/44
Age (year)b 21 (11) 22 (12)
Dengue serotype
DENV-1 (%) 20 (28.17) 25 (24.75)
DENV-2 (%) 27 (38.03) 32 (31.69)
DENV-3 (%) 17 (23.94) 30 (29.70)
DENV-4 (%) 7 (9.86) 14 (13.86)
Degree of hemoconcentration (%)b 12.67 (7.03)* 18.92 (10.81)*
Lowest albumin concentration at critical phase (g/dL)b 3.70 (0.35)* 3.31 (0.46)*
Degree of hypoalbuminemia (%)b 11.36 (9.00)* 20.63 (12.67)*
Lowest platelet count (x 1,000/μL)b 75.00 (66.00)* 32.00 (31.50)*
Elevated ratio of ASTb 1.80 (1.46)* 3.11 (2.84)*
Elevated ratio of ALTb 0.88 (1.00) * 1.22 (1.16)*
Sodium concentration at critical phase (mEq/L)a 135.37 ± 5.83 134.05 ± 5.09
ALT alanine aminotransferase, AST aspartate aminotransferase
adata presented as the mean ± standard deviation
bdata presented as median (interquartile range)
*p < 0.05 by Mann Whitney test
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(Table 1). We determined the best cut off value of those
six significant variables using receiving operating charac-
teristic (ROC) curve analysis (Table 2) as the reference
for classifying those predictors into categorical variables.
There are two albumin related diagnostic predictors of
pleural effusion and/or ascites, i.e., the lowest albumin
concentration at the critical phase (≤3.49) and the de-
gree of hypoalbuminemia (>15.6 %; Table 2). Those two
variables have a similar AROC. For practicality, we se-
lected the lowest albumin concentration at the critical
phase as the predictor of pleural effusion and/or ascites
because it is only measured once.
The bivariate analyses to predict pleural effusion and/or
ascites using the five variables are presented in Table 3.
All variables with a significant effect based on the bivariate
analysis were then subjected to a multivariate analysis.
The following variables were found to be independent
diagnostic predictors of pleural effusion and/or ascites: de-
gree of hemoconcentration ≥15.1 %, lowest albumin con-
centration at the critical phase ≤3.49 g/dL, lowest platelet
count ≤49,500/μL, and elevated ratio of AST ≥2.51
(Table 3).
Scoring system development
The Dengue Score was generated by dividing each
multivariate logistic regression coefficient by the smallest
coefficient in the model (elevated ratio of AST ≥2.51).
The score weights were calculated by dividing the coeffi-
cient/standard error (2.38) as follows: degree of hemo-
concentration >15.1 %, lowest albumin concentration at
critical phase ≤3.49 mg/dL, lowest platelet count
≤49,500/μL, resulting in quotients of 1.17, 1.40, and
1.24, respectively. The quotients were rounded to the
nearest integer, resulting in score weights of one for each
variable (Table 3).
Performance of the score
The Dengue Score was tested at different cut off values,
and the results are shown in Table 4. At a cut off of ≥ 2,
the score had a sensitivity of 82.47 %, specificity of
70.42 %, positive predictive value (PPV) 79.21 %,
negative predictive value (NPV) of 74.63 %, and correctly
predicted pleural effusion and/or ascites diagnosis at a
rate of 77.38 %. The AROC of the logistic regression
probability model was 86.02 % (95 % CI: 80.3–91.8 %),
and the Dengue Score AROC was 85.36 % (95 % CI:
79.5–91.2 %). The significance levels of the AROC of the
2 models were comparable (p = 0.34; Fig. 2). The model
fitted the observed data according to the Hosmer-
Lemeshow goodness-of-fit test (p =0.362).
Discussion
This is the first Indonesian study to determine a scoring
system to predict pleural effusion and/or ascites in adult
patients with dengue infection. Michels et al. and
Balasubramanian et al. showed that pleural effusion and/
or ascites detection by USG is superior to clinical and
laboratory parameters for diagnosing plasma leakage
[15, 16]. In this study, we tried to determine inde-
pendent diagnostic predictors of pleural effusion and/
or ascites and to convert the prediction model into a
scoring system that could be practically used because USG
is not routinely available in all healthcare facilities.
Hematocrit, albumin, hepatic transaminases, platelet count,
and sodium concentrations are laboratory parameters that
are routinely checked in the management of dengue pa-
tients as recommended by the WHO [2, 5, 10]. Therefore,
the scoring system to predict the plasma leakage that was
represented in this study by the detection of pleural effu-
sion and/or ascites would be highly applicable in various
healthcare settings where USG is not available.
As reported in other study, there is a significant differ-
ence in the degree of hemoconcentration in dengue in-
fected patients with and without pleural effusions and/or
ascites [28]. We found a similar result, with a degree of
hemoconcentration of 12.67 % (inter-quartile range - IQR
7.03 %) in patients without pleural effusion/ascites and
18.92 % (IQR 10.81 %) in patients with pleural effusion/as-
cites. Translating this finding, DHF would be underdiag-
nosed by physicians relying only on hematocrit as a
diagnostic criterion. The ROC analysis showed that com-
pared with classically used cut off point of degree of
Table 2 Receiver operator curve characteristics for significant parameters in predicting pleural effusion and/or ascites diagnosis and
cut off value for maximum sensitivity and specificity
Variable AROC (95 % CI) Cut off Sens (%) Spe (%) LR+ LR-
Degree of hemoconcentration (%) 0.74 (0.67–0.82) ≥15.10 67.3 69 2.17 0.47
Lowest albumin concentration at critical phase (mg/dL) 0.78 (0.72–0.86) ≤3.49 70 81.7 3.78 0.37
Degree of hypoalbuminemia (%) 0.76 (0.69–0.84) ≥15.6 74.2 72.3 2.68 0.36
Lowest platelet count (/μL) 0.83 (0.76–0.89) ≤49,500 72.3 76.1 3.02 0.36
Elevated ratio of AST 0.77 (0.70–0.85) ≥2.51 70.1 74.29 2.72 0.40
Elevated ratio of ALT 0.63 (0.54–0.71) ≥1.01 64.9 57.7 1.51 0.60
ALT alanine aminotransferase, AST aspartate aminotransferase, AROC area under receiving operating characteristic curve, LR- negative likelihood ratio, LR+ positive
likelihood ratio, CI confident interval, Sens sensitivity, Spe specificity
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hemoconcentration ≥20 % as suggested by the WHO
[5, 10], a cut off point ≥15.1 % gives a better performance
for predicting the presence of pleural effusion and/or asci-
tes. Our study suggests the use of the lowest cut off point
of hemoconcentration to define plasma leakage to
minimize the risk of under-diagnosing patients at risk of
severe dengue. A degree of hemoconcentration ≥15.1 %
was given a score of 1 in the final Dengue Score.
The WHO defines a significantly decreased albumin
>0.5 g/dL from baseline or <3.5 g/dL as indirect evi-
dence of plasma leakage [2, 10]. However, two publica-
tions reported low albumin levels (<3.5 g/dL) in patients
with DF and DHF [11, 12]. Jagadishkumar et al. [11] and
Itha et al. [12] found median albumin levels of 3.1 g/dL
to 3.37 g/dL in DF and 2.7 g/dL to 3.23 g/dL in DHF
groups based on the WHO criteria. Roy et al. [13] re-
ported that mean albumin levels in dengue-infected pa-
tients without and with warning signs were 3.48 and
3.34 g/dL, respectively. We observed that the use of two
albumin-related parameters, i.e., the lowest albumin con-
centration at the critical phase and the degree of hypoal-
buminemia, for predicting a diagnosis of pleural effusion
and/or ascites may not be conclusive. We found that
≤3.49 g/dL and ≥15.6 % were the best cut off points for
the two parameters, respectively. We suggest using de-
gree of hypoalbuminemia as a percentage to detect
plasma leakage, similar to the concept of degree of
hemoconcentration. However, due to the similarity in
AROC between the 2 parameters, we selected the lowest
albumin concentration at critical phase, which is more
practical in daily practice, as albumin is only measured
once at critical phase. In DHF, hypoalbuminemia results
from the loss of albumin due to the occurrence of
plasma leakage. This phenomenon is similar with the
pathophysiology of pleural effusion and/or ascites in DHF,
thereby explaining the association between the two condi-
tions [29]. Similar with degree of hemoconcentration, low-
est albumin concentration at critical phase ≤3.49 g/dL was
given a score of 1 in the final Dengue Score.
Thrombocytopenia has been accepted as a major sign of
plasma leakage in dengue-infected patients. Damage to
platelets, which possibly contribute to thrombocytopenia in
dengue patients, results in the release of vascular endothe-
lial growth factor (VEGF) which in turn is responsible for
the occurrence of pleural effusions and/or ascites [30, 31].
As shown in Table 1, we found a significant difference in
the medians between patient with and without pleural effu-
sion and/or ascites. Using cut off point of ≤49,500/μL, it
gave the best AROC among all the variables tested. This
variable was given a score of 1 in the final Dengue Score.
Our data show that liver injury, manifested by an ele-
vated ratio of hepatic transaminases, was frequently
present in adult patients with dengue infection. Liver
cells are one of the targets of dengue viruses. The liver
dysfunction was mild to moderate, presenting primarily
as elevations of hepatic transaminases, with significantly
higher AST elevation in patients with pleural effusion
and/or ascites [32, 33]. Consistent with the findings of
Mahmuduzzaman et al. [34], we found a greater increase
of AST compared with ALT in dengue patients. In the
multivariate analysis, an elevated ratio of ALT failed to
show a significant association with pleural effusion and/
or plasma leakage. The exact significance of the greater
elevation of AST compared with ALT in dengue might
be because of the excess release of AST from damaged
myocytes during dengue infections [35]. Further re-
search is needed to confirm this hypothesis. An elevated
ratio of AST is a laboratory marker of dengue severity
that has been proposed by several researchers but has
not gained much attention, as reflected by its absence in
the plasma leakage criteria of the WHO [2, 5, 10]. By
calculating the transaminase elevation ratio, we are
attempting to address the problem of the difference be-
tween laboratories in the reference limits of the AST
[36]; therefore, this diagnostic predictor variable could
be universally used across laboratories.
Table 3 Final multiple logistic regression model to predict pleural effusion and/or ascites
Variable Bivariate analysis Multivariate adjusted
Odds ratio (95 % CI) p Value Coefficient Odds ratio (95 % CI) p Value Dengue Score
Degree of hemoconcentration≥ 15.1 % 4.30 (2.25–8.22) <0.001 1.13 3.11 (1.41–6.88) 0.005 1
Lowest albumin concentration at critical phase ≤3.49 g/dL 10.07 (4.83–21.01) <0.001 1.50 4.48 (1.87–10.77) 0.001 1
Lowest platelet count≤ 49,500/μL 8.28 (4.12–16.64) <0.001 1.28 3.62 (1.55–8.49) 0.003 1
Elevated ratio of AST≥ 2.51 4.94 (2.54–9.62) <0.001 0.98 2.67 (1.19–5.97) 0.017 1
Elevated ratio of ALT ≥ 1.01 2.50 (1.33–4.70) 0.004
ALT alanine aminotransferase, AST aspartate aminotransferase, CI confident interval
Table 4 The sensitivity and specificity of the Dengue Score at
different cut offs
Cut off Sensitivity Specificity PPV NPV Correctly Classified
≥1 98.97 % 40.85 % 69.57 % 96.67 % 74.40 %
≥2 82.47 % 70.42 % 79.21 % 74.63 % 77.38 %
≥3 65.98 % 88.73 % 88.89 % 65.63 % 75.60 %
≥4 26.80 % 97.10 % 92.86 % 49.29 % 56.55 %
NPV negative predictive value, PPV positive predictive value
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This study has limitation that should be considered.
This study was conducted in patients without comorbid-
ities; therefore, the generalization should be re-tested in
population with comorbidities, especially in those with
comorbidities that potentially influencing the levels/con-
centration of predictors’ variables, e.g., chronic kidney
disease and chronic liver disease. Future study is needed
to validate the Dengue Score and to investigate the effect
of the application of this Dengue Score in various
healthcare facilities managing dengue-infected patients.
Conclusions
We have developed a Dengue Score to predict the diagno-
sis of a pleural effusion and/or ascites in adults with den-
gue infection. This score might provide early identification
of patients who are at risk for developing severe dengue.
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